RXRX

Recursion Pharmaceuticals, Inc.

9.26 USD
-0.18 (-1.91%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Recursion Pharmaceuticals, Inc. stock is down -2.63% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 Jun 16:36 20 Sep, 2024 12.00 PUT 184 1957
10 Jun 16:35 20 Sep, 2024 8.00 CALL 641 2292
11 Jun 17:05 20 Sep, 2024 12.00 PUT 67 2173
12 Jun 13:31 20 Sep, 2024 9.00 CALL 1000 1605
12 Jun 13:55 16 Jan, 2026 25.00 CALL 149 312
12 Jun 15:56 17 Jan, 2025 5.00 CALL 100 1121
12 Jun 18:39 16 Jan, 2026 10.00 CALL 77 1090
13 Jun 15:01 17 Jan, 2025 12.50 CALL 198 3240
13 Jun 15:25 20 Sep, 2024 11.00 PUT 100 766
14 Jun 14:04 17 Jan, 2025 11.00 PUT 105 76

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation. REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer.